Related Experiment Video

Updated: Apr 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma

Gordana Vlahovic1, Peter E Fecci1, David Reardon1

  • 1Division of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina (G.V., P.E.F., J.H.S.); Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, Massachusetts (D.R.).

Neuro-Oncology
|May 13, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K